FDA Labeling Proposal Should Allow "Flexible" Warnings, Merck Tells Agency
Executive Summary
Standardized headings in the "Warnings/Precautions" section of labeling would inappropriately limit manufacturer flexibility in communicating drug risk information, Merck said in comments on the agency's labeling rewrite proposed rule.
You may also be interested in...
Rx Label Format Changes Should Be Phased In Without "Highlights" - PhRMA
FDA's prescription drug labeling initiative should proceed in areas where there is consensus between the agency and the pharmaceutical industry, the Pharmaceutical Research & Manufacturers of America said in comments on the proposed rule.
Rx Label "Highlights" Under FDA Rule Could Yield Inconsistencies - Merck
Information included in the "Highlights" summary section of drug labeling under FDA's proposed rule would likely be inconsistent from product to product, Merck said in comments on FDA's proposed labeling rule.
Indication, Warning Summaries In Labeling "Highlights" - FDA Rule
The new Highlights section of labeling under FDA's proposed labeling rule would feature a summary of the product's indication rather than the indication verbatim.